route to commercial success15 Jul 2022 13:46
opportunity!!!
Nigel Theobald, Chief Executive Officer of the Company, commented:
"We continue to make good progress in understanding how Nuvec® can be used in the oncology space and this work, combined with the potential opening up of the siRNA market and the early data coming from UQ on their oral work, gives us a lot of material to further focus our route to commercial success."